Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2002;40:647-652
Published online before print October 7, 2002, doi: 10.1161/01.HYP.0000036399.80194.D8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/5/647    most recent
01.HYP.0000036399.80194.D8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grandi, A. M.
Right arrow Articles by Venco, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grandi, A. M.
Right arrow Articles by Venco, A.
Related Collections
Right arrow Remodeling
Right arrow Clinical Studies

(Hypertension. 2002;40:647.)
© 2002 American Heart Association, Inc.


Scientific Contributions

Aldosterone Antagonist Improves Diastolic Function in Essential Hypertension

Anna M. Grandi; Daniela Imperiale; Rosa Santillo; Elena Barlocco; Andrea Bertolini; Luigina Guasti; Achille Venco

From the Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy.

Correspondence to Anna Maria Grandi, MD, via Bagaini 15, 21100 Varese, Italy. E-mail amgrandi{at}libero.it

Experimental studies demonstrated that mineralocorticoid antagonists prevent or reverse myocardial fibrosis. Therefore, we tested the hypothesis that the aldosterone antagonist canrenone can improve left ventricular diastolic function in essential hypertension. Using digitized M-mode echocardiography and 24-hour blood pressure monitoring (ABPM), we realized a prospective, randomized, controlled study on 34 never-treated essential hypertensives with left ventricular diastolic dysfunction. Echocardiogram and ABPM were repeated after 6 months of effective antihypertensive treatment with ACE inhibitors and calcium antagonists (second evaluation) and then after a 6-month period with 17 patients randomly assigned to add canrenone 50 mg/d to the previous treatment (third evaluation). At the basal evaluation 32 patients had left ventricular concentric hypertrophy, and 2 patients had left ventricular concentric remodeling. All the patients had normal left ventricular systolic function. At the second evaluation blood pressure was reduced (P<0.0001), left ventricular mass index decreased (P<0.0001), and diastolic function improved (P<0.0001). After randomization, the canrenone and control groups had similar 24-hour blood pressure and left ventricular morpho-functional characteristics. At the third evaluation, despite unchanged blood pressure and similar decrease of left ventricular mass index, the canrenone group, compared with control group, showed a significantly greater increase in left ventricular diastolic indices. In essential hypertension, a low dose of aldosterone antagonist added to antihypertensive treatment significantly improved left ventricular diastolic function. This improvement, not accounted for by changes in blood pressure and left ventricular mass, can be therefore ascribed to a direct action of the drug on the myocardium.


Key Words: aldosterone • diastole • hypertension, essential • antihypertensive therapy • fibrosis • ventricular function, left




This article has been cited by other articles:


Home page
Ther Adv Cardiovasc DisHome page
M. M. Shafiq and A. B. Miller
Blocking aldosterone in heart failure
Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 379 - 385.
[Abstract] [PDF]


Home page
J Clin PharmacolHome page
A. H. Karara, V. Hanes, A. Alonso, P. Ni, N. Poola, R. Silang, H. Blode, and R. A. Preston
Pharmacokinetics and Pharmacodynamics of Drospirenone-Estradiol Combination Hormone Therapy Product Coadministered With Hydrochlorothiazide in Hypertensive Postmenopausal Women
J. Clin. Pharmacol., October 1, 2007; 47(10): 1292 - 1302.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis
Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure
Mayo Clin. Proc., December 1, 2005; 80(12): 1623 - 1630.
[Abstract] [PDF]


Home page
J Am Board Fam MedHome page
S. Haney, D. Sur, and Z. Xu
Diastolic Heart Failure: A Review and Primary Care Perspective
J Am Board Fam Med, May 1, 2005; 18(3): 189 - 198.
[Abstract] [Full Text] [PDF]